Physician profile
Todd E Pesavento
NPI 1629085030
$20,100.19
in general payments reported to CMS, 2019-2025
6 companies · $1.66 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,251 · 2023: $8,162 · 2024: $8,686 · 2025: $1.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,716 · Consulting Fee: $6,852 · Food and Beverage: $280 · Education: $1.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,715.80 |
| Consulting Fee | $6,852.00 |
| Food and Beverage | $280.01 |
| Education | $1.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $8,686.22 | 2024 | Vyvgart Hytrulo |
| Sanofi-Aventis U.S. LLC | $8,161.59 | 2023 | |
| Csl Behring | $3,250.72 | 2022 | |
| Travere Therapeutics, INC. | $1.66 | 2025 | Filspari |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Pesavento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.